126.89
-0.73 (-0.57%)
| Previous Close | 127.62 |
| Open | 127.42 |
| Volume | 64,910 |
| Avg. Volume (3M) | 920,290 |
| Market Cap | 4,336,379,904 |
| Price / Earnings (TTM) | 49.96 |
| Price / Earnings (Forward) | 52.36 |
| Price / Sales | 9.43 |
| Price / Book | 13.13 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | 10.03% |
| Operating Margin (TTM) | 19.12% |
| Diluted EPS (TTM) | 1.42 |
| Quarterly Revenue Growth (YOY) | 48.20% |
| Quarterly Earnings Growth (YOY) | 110.60% |
| Total Debt/Equity (MRQ) | 194.67% |
| Current Ratio (MRQ) | 9.10 |
| Operating Cash Flow (TTM) | 49.38 M |
| Levered Free Cash Flow (TTM) | -84.81 M |
| Return on Assets (TTM) | 4.21% |
| Return on Equity (TTM) | 22.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | TransMedics Group, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -2.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.40 |
|
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.03% |
| % Held by Institutions | 121.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 166.00 (Needham, 30.82%) | Buy |
| Median | 146.00 (15.06%) | |
| Low | 135.00 (Morgan Stanley, 6.39%) | Hold |
| Average | 148.00 (16.64%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 130.14 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 08 Dec 2025 | 166.00 (30.82%) | Buy | 136.60 |
| 23 Oct 2025 | 148.00 (16.64%) | Buy | 128.91 | |
| Morgan Stanley | 02 Dec 2025 | 135.00 (6.39%) | Hold | 141.77 |
| Canaccord Genuity | 30 Oct 2025 | 147.00 (15.85%) | Buy | 135.79 |
| 14 Oct 2025 | 142.00 (11.91%) | Buy | 111.23 | |
| Piper Sandler | 30 Oct 2025 | 140.00 (10.33%) | Buy | 135.79 |
| Jefferies | 13 Oct 2025 | 145.00 (14.27%) | Buy | 111.71 |
| Evercore ISI Group | 16 Sep 2025 | 155.00 (22.15%) | Buy | 119.15 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HERNANDEZ GERARDO | - | 138.63 | -920 | -127,540 |
| WEILL DAVID | - | 140.10 | -5,000 | -700,500 |
| Aggregate Net Quantity | -5,920 | |||
| Aggregate Net Value ($) | -828,040 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 139.37 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HERNANDEZ GERARDO | Officer | 04 Dec 2025 | Sell (-) | 920 | 138.63 | 127,540 |
| WEILL DAVID | Director | 03 Dec 2025 | Sell (-) | 5,000 | 140.10 | 700,500 |
| WEILL DAVID | Director | 03 Dec 2025 | Option execute | 5,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 18 Nov 2025 | Announcement | TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference |
| 31 Oct 2025 | Announcement | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 29 Oct 2025 | Announcement | TransMedics Reports Third Quarter 2025 Financial Results |
| 15 Oct 2025 | Announcement | TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025 |
| 22 Sep 2025 | Announcement | TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |